David B. MacLean
23Patents
8h-index
6Co-inventors
68Inventor score
Filing activity: Feb 21, 1997 → Nov 5, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5889042A | Method of treating diseases and conditions with estrogen agonists and antagonists | Human Necessities | 29 | Expired |
| US6107331A | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | Human Necessities | 26 | Expired |
| US6017964A | Method of increasing testosterone | Human Necessities | 12 | Expired |
| US10449191B2 | Treatment of prostate cancer | Human Necessities | 11 | Active |
| US10786501B2 | Treatment of prostate cancer | Human Necessities | 10 | Active |
| US6355670B1 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | Human Necessities | 10 | Expired |
| US6613796B2 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | Human Necessities | 9 | Expired |
| US6911456B2 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | Human Necessities | 9 | Expired |
| US11583526B2 | Treatment of prostate cancer | Human Necessities | 8 | Active |
| US6274618A | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | Human Necessities | 8 | Expired |
| US5861438A | Combination therapy to prevent bone loss parathyroid hormone and estrogen agonists | Human Necessities | 8 | Expired |
| US6403611B2 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions | Human Necessities | 8 | Expired |
| US5773477A | Combination therapy to treat osteoporosis - polyphosphonates and estrogen agonists | Human Necessities | 5 | Expired |
| US5719190A | Inhibition of myeloperoxidase activity | Human Necessities | 5 | Expired |
| US5719191A | 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease | Human Necessities | 4 | Expired |
| US12097198B2 | Treatment of prostate cancer | Human Necessities | 3 | Active |
| US12144809B1 | Treatment of prostate cancer | Human Necessities | 2 | Active |
| US5726207A | Protection of ischemic myocardium against reperfusion damage | Human Necessities | 1 | Expired |
| US6100301A | Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists | Human Necessities | 1 | Expired |
| US5733937A | Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder | Human Necessities | 1 | Expired |
| US5985932A | Inhibition of autoimmune diseases | Human Necessities | 0 | Expired |
| US6057309A | Combination therapy to prevent bone loss-progesterone and estrogen agonists | Human Necessities | 0 | Expired |
| US12336990B2 | Treatment of prostate cancer | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.